Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases

• Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
• Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
• Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning

Speakers:

Thomas Hansen

Chief Technology Officer

Circio ASA

Thimmaiah Chendrimada

Founder

Able Sciences

Marc Talló-Parra

Chief Scientific Officer

NoctuRNA Therapeutics

Cory Sago

Chief Executive Officer & Founder

Amplitude Therapeutics